Plain-English translation of NCT06836232 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called to see if it can safely treat recurrent pericarditis — a condition where the tissue surrounding your heart becomes inflamed over and over. The study will enroll about 50 people in three different groups, each trying slightly different doses or schedules of the medication to find what works best and causes the fewest side effects.
Recurrent pericarditis can be painful and frustrating to manage with current treatments, and many patients need better options. This study exists to see if this medication could offer relief for people whose heart lining keeps becoming inflamed despite standard care.
You likely qualify if…
You likely don't qualify if…
You'll first go through a screening period (about 30 days) to confirm you qualify. Then, depending on which group you're assigned to, you'll take the medication for 6 to 18 weeks while visiting the clinic regularly so doctors can monitor how you're doing and check for any side effects. The study includes blood tests, symptom assessments, and follow-up visits to make sure the treatment is working and is safe for you.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States